United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Here's one genetics play that you might want to put on your radar.

This Genetics Stock Could Have a Bright Future

BioNTech SE

Israel's Health Ministry has reportedly found the small number of heart inflammation cases, observed mainly in young men who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine in Israel, were likely linked to their vaccination. Pfizer said that it was aware of the Israeli observations of myocarditis and said no causal link to its vaccine had been established.

Myocarditis Cases Probably Linked to Pfizer COVID-19 Vaccine, Says Israel Health Ministry: Reuters

Israel recorded 275 cases of myocarditis between December 2020 and May 2021 among more than 5 million vaccine recipients.

Israel Sees ‘Probable Link' Between Pfizer Vaccine And Small Number Of Heart Inflammation Cases

Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU

mRNA vaccines are a revolution because they allow rapid vaccine development and scale up of manufacture. mRNA technology is about tricking humans to make proteins; there will be other applications beyond vaccines.

Pfizer: mRNA COVID Vaccine Is Transforming And More To Come

Intel

Tesla

Moderna

Canadian Pension Plan Investment Board cut more than three-quarters of positions in chip giant Intel and electric-vehicle maker Tesla, and bought Moderna and Pfizer stock in the first quarter.

Giant Pension Slashed Intel, Tesla Stakes. It Scooped Up Covid-Vaccine Makers.

Johnson & Johnson

The combination of stability and innovation makes these giants safe bets for long-term returns.

2 Healthcare Stocks That Could Be Millionaire-Makers

Align Technology

DermTech Inc

You definitely don't want to overlook their growth prospects.

3 Overlooked Healthcare Stocks to Buy Right Now

European Medical Agency backed the use of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children as young as 12, paving the way for a broader roll-out in Europe, reports Reuters. The endorsement comes weeks after it began evaluating extending the use of the vaccine to include 12- to 15-year-olds.

European Drug Regulator Supports Use Of Pfizer-BioNTech COVID-19 Vaccine In Adolescents: Reuters

The European drugs regulator has authorized the use of the Pfizer-BioNTech COVID-19 vaccine on children aged 12 to 15, it said on Friday.

European regulator approves Pfizer-BioNTech vaccine for children 12-15

The answer is better than you might think.

How are Pfizer's and Moderna's Vaccines Faring Against Coronavirus Variants?

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings al

AM Best Affirms Credit Ratings of Blue Whale Re Ltd.

As a step to accelerate vaccination rollout, India has reportedly scrapped local trials for “well-established” foreign COVID-19 vaccines, with a government official saying Pfizer Inc (NYSE: PFE) shots could arrive by July. Only about 3% of India's 1.3 billion people have been fully vaccinated, the lowest rate among the ten countries with the most cases.

India To Skip Local Trials for 'Well Established' COVID-19 Vaccines; Pfizer Shots May Arrive By July: Reuters

Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.

Here's Why Pfizer (PFE) Has Been Rallying This Year So Far

Myovant Sciences

The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc's (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibroids in premenopausal women. The once-daily treatment will be marketed as Myfembree, with a treatment duration of up to two years.

Myovant - Pfizer's Uterine Fibroids Treatment Wins FDA Approval

On Tuesday, Reuters reported that the EU is targeting more than 1 billion COVID-19 shots by September. This is a huge figure considering that since the vaccine roll-outs began earlier this year, only 266 million vaccinations have been administered in the European Union.

Best COVID-19 vaccine stock to buy in June: Pfizer

Dyadic International Inc., DE

Novavax

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of the major vaccine-oriented pharma players. Vax 2.0 is no longer a theory.

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

Coca-Cola

Southern Company

Income-seeking investors may want to shop around before taking the plunge on the drinks and snacks name.

3 Dividend Stocks That Pay You More Than Pepsi Does

There's arguably never been a product with a greater chance of FDA approval.

Why FDA Approval for Pfizer's COVID Vaccine Would Be a Slam Dunk For the Long Run

This potential market is definitely large enough to motivate drugmakers to go after it.

How Big Is the COVID Vaccine Market for Younger Kids?

Are Pfizer and Moderna Trying to Boost Sales With an Early COVID Booster Shot?

Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.

Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo

Amgen

Bristol-Myers

General Dynamics

Lockheed Martin

Merck

7 High-Quality Dividend Growth Stocks Trading Below Fair Value

There's a sizable opportunity for Pfizer, but one that probably won't make the company significant revenue until next year.

News for Pfizer Stock (PFE)